查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1808353

生物技術與製藥服務外包市場按服務類型、外包類型、公司規模、治療領域和服務供應商類型分類 - 全球預測，2025-2030 年

Biotechnology & Pharmaceutical Services Outsourcing Market by Service Type, Mode of Outsourcing, Company Size, Therapeutic Area, Service Provider Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

生技和製藥服務外包市場預計到 2024 年將達到 554.2 億美元，2025 年將達到 585.4 億美元，到 2030 年將達到 773.8 億美元，複合年成長率為 5.71%。

主要市場統計數據
基準年2024年 554.2億美元
預計2025年 585.4億美元
預測年份 2030 773.8億美元
複合年成長率（%） 5.71%

探索塑造當今生物技術和製藥外包產業的策略基礎和關鍵促進因素

生物技術和製藥服務外包行業正處於關鍵的十字路口，受治療創新的不斷發展和成本壓力的不斷增加的驅動。細胞和基因療法的快速發展，加上日益複雜的臨床和監管要求，正在推動對外部專業知識的需求。同時，企業正面臨嚴格的審查，以加快上市時間、維持品質標準並最佳化資本配置。

檢驗正在重新定義醫藥外包領域服務交付的重大技術進步和營運轉型

近年來，隨著先進的分析工具和自動化平台重新定義了營運預期，外包格局發生了重大轉變。人工智慧驅動的研究設計和機器學習主導的數據分析正在支撐決策支援系統，並加速化合物選擇和患者招募策略。同時，雲端基礎的協作入口網站已成為即時資料交換的關鍵，有助於提高地理位置分散的團隊之間的透明度和合規性。

揭示2025年美國關稅對生物技術和製藥外包的更廣泛的經濟和貿易政策影響

美國將於2025年實施新的關稅制度，這將在從海外合作夥伴採購實驗室用品、原料藥和設備時引入複雜的成本和合規考量。依賴全球供應鏈的製造商和臨床研究機構正面臨不斷上漲的關稅，這促使他們重新評估其供應商組合和物流網路。為了應對這些不利因素，許多相關人員正在探索近岸外包方案，並與國內受託製造廠商合作，以規避關稅的影響。

探索細分洞察，揭示服務類型、外包模式、公司規模、治療領域和提供者類型將如何影響產業成長

對市場區隔進行嚴格的檢驗，可以發現各種服務類型（從臨床試驗階段到複雜的監管策略支援）的需求促進因素存在細微差別。 I期至IV期臨床試驗服務持續受到廣泛關注，因為申辦方尋求端到端患者招募和場地管理方面的專業知識；而諮詢服務（包括併購諮詢和打入市場策略）也擴大被用於應對不斷變化的報銷制度。

分析美洲、歐洲、中東和非洲地區以及亞太地區外包產業的獨特監管環境和創新能力

不同地區擁有不同的創新生態系統和法律規範都會影響外包策略。在美洲，生物技術中心和頂級臨床機構的集中推動了對全方位服務解決方案的需求，而積極的貿易政策和獎勵則推動了國內製造業的擴張。不斷變化的報銷模式以及對以患者為中心的臨床試驗的關注，正在推動分散式臨床服務的成長。

評估塑造生物製藥行業的領先委外研發機構和諮詢公司的競爭方式、夥伴關係和成長路徑

領先的合約研究機構正透過策略聯盟、地理擴張和端到端平台整合來脫穎而出。一些主要企業正在尋求與專業的生物技術公司建立合資企業，共同開發細胞療法生產和高級分析領域的利基能力。這些聯盟增強了他們的服務組合，並加速了最尖端科技的獲取。

生物製藥外包領導者提供可行的策略建議，以最佳化服務交付創新和營運彈性

產業領導者應優先投資數位平台，以促進全球企劃團隊之間的無縫協作，並加速即時數據視覺化。採用先進的分析技術和人工智慧主導的決策支援工具，不僅可以簡化研究設計和病患招募，還能增強監管鏈中的風險管理和品質監督。

結合主要專家訪談、全面的二次研究和數據三角測量方法的嚴謹多模態調查方法的詳細資訊

研究採用全面的多模態方法，首先廣泛查閱同行評審出版物、行業白皮書和監管文件，以建立堅實的二手資料基礎。此外，研究還整合了政府資料庫和專業產業報告的關鍵見解，以全面檢驗市場趨勢和政策發展。

全面檢視關鍵趨勢：醫藥服務外包相關人員的策略意義與未來前景

在技​​術創新、貿易政策演變和客戶偏好變化的推動下，生物技術和製藥服務外包生態系統正在迅速成熟。策略合作、數位轉型和地理擴張正成為企業成長和韌性的關鍵槓桿。為了滿足這些需求，企業必須在專業知識需求與一體化服務模式所帶來的效率之間取得平衡。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 快速採用人工智慧平台加速合約研究服務中的藥物發現
  • 個人化醫療需求的不斷成長推動了專業外包解決方案的擴張
  • 細胞和基因治療外包的快速成長需要擴大專業製造能力
  • 在製藥外包業務中融入永續性和綠色化學實踐
  • 真實世界證據和數據分析在製定外包臨床試驗策略中的作用日益增強
  • CDMO之間的整合推動了生物製造服務領域的策略夥伴關係和產能最佳化
  • 影響臨床試驗和藥物核准全球外包的監管協調舉措
  • 醫藥服務外包合約中更重視風險緩解和供應鏈彈性
  • 數位化病人參與工具的出現改變了臨床試驗的現場管理和遠端監控
  • 實施連續生產流程，加速外包合約設施的生物製藥生產

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 生技和製藥服務外包市場（依服務類型）

  • 臨床試驗服務
    • 第一階段
    • 第二階段
    • 第三階段
    • 第四階段
  • 諮詢服務
    • 併購諮詢
    • 市場進入及報銷諮詢
    • 投資組合管理
    • 策略諮詢
  • 製造服務
    • API 製造
    • 合約開發與製造組織 (CDMO) 服務
    • 灌裝和精加工服務
    • 配方開發
    • 包裝和標籤
    • 擴大規模和技術轉移
  • 藥物警戒服務
  • 臨床前服務
    • 動物實驗
    • 生物分析測試
    • DMPK研究
    • 藥理學研究
    • 毒性測試
  • 品管服務
  • 監管服務
    • 代理通訊及代表
    • 文件準備
    • 標籤和包裝合規性
    • 藥物警戒和安全監測
    • 監理策略和備案
  • 研發服務
    • 檢測方法開發
    • 生物標記發現
    • 線索識別和最佳化
    • 目標檢驗

9. 生技和製藥服務外包市場（依外包類型）

  • 全方位服務外包
  • 功能服務供應商（FSP）模型
  • 戰術性/企劃為基礎的外包

第 10 章：生物技術和製藥服務外包市場（按公司規模）

  • 主要企業
  • 小型企業

第 11 章。生物技術和製藥服務外包市場（按治療領域）

  • 心血管系統
  • 皮膚科
  • 胃腸病學
  • 免疫學
  • 感染疾病
  • 代謝紊亂
  • 神經病學
  • 腫瘤學
  • 小兒科
  • 罕見疾病
  • 呼吸系統

第 12 章：生物技術和製藥服務外包市場（按服務供應商類型）

  • 顧問公司
  • 合約開發和製造組織（CDMO）
  • 契約製造組織（CMO）
  • 合約研究組織（CRO）
  • 資料管理和 IT服務供應商
  • 監管事務公司

13.美國生技與製藥服務外包市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14.歐洲、中東和非洲生物技術和製藥服務外包市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太生物技術和製藥服務外包市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AmerisourceBergen Corporation
    • Catalent, Inc.
    • CEVA Logistics AG
    • Charles River Laboratories, Inc.
    • Concept Heidelberg GmbH
    • Curia Global, Inc.
    • Dalton Pharma Services by Seikagaku Corporation
    • DHL International GmbH
    • Eurofins Scientific（Ireland）Limited
    • Evotec SE
    • GenScript Biotech Corporation
    • Icon PLC
    • IQVIA HOLDINGS, INC.
    • Laboratory Corporation of America Holdings
    • Lachman Consultant Services, Inc.
    • McKesson Corporation by Aurelius Group
    • Medpace Holdings, Inc.
    • Parexel International Corporation
    • Syneos Health, Inc.
    • Thermo Fisher Scientific Inc.
    • WuXi AppTec Co., Ltd.

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-3A2E844FE146

The Biotechnology & Pharmaceutical Services Outsourcing Market was valued at USD 55.42 billion in 2024 and is projected to grow to USD 58.54 billion in 2025, with a CAGR of 5.71%, reaching USD 77.38 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 55.42 billion
Estimated Year [2025] USD 58.54 billion
Forecast Year [2030] USD 77.38 billion
CAGR (%) 5.71%

Discovering the Strategic Foundations and Critical Drivers Shaping the Biotechnology and Pharmaceutical Outsourcing Industry Today

The biotechnology and pharmaceutical services outsourcing sector stands at a pivotal juncture, driven by evolving therapeutic innovations and mounting cost pressures. Rapid advancements in cell and gene therapies, coupled with the increasing complexity of clinical and regulatory requirements, have expanded the demand for specialized external expertise. Meanwhile, organizations are under relentless scrutiny to accelerate time to market, maintain quality standards and optimize capital deployment.

Within this dynamic environment, outsourcing partners play an instrumental role in augmenting in-house capabilities and mitigating operational risks. An array of service models now spans from full-service contract research organizations to tactical project-based support, allowing companies to tailor collaborations according to strategic imperatives. In parallel, digital transformation initiatives are reshaping traditional workflows, driving deeper integration between sponsors and service providers.

As industry stakeholders adapt to these shifts, understanding the strategic foundations and key drivers becomes essential for informed decision making. This introduction sets the stage by outlining core market catalysts such as regulatory complexity, technological innovation and economic considerations. By contextualizing these forces, readers will gain clarity on the factors shaping service demand and partnership models, preparing them to navigate an increasingly competitive and interconnected outsourcing landscape.

Examining the Dramatic Technological Advancements and Operational Transformations Redefining Service Delivery in the Pharmaceutical Outsourcing Landscape

In recent years, the outsourcing landscape has undergone profound transformation as advanced analytical tools and automation platforms have redefined operational expectations. Artificial intelligence-powered trial designs and machine learning-driven data analytics now underpin decision support systems, accelerating compound selection and patient recruitment strategies. Concurrently, cloud-based collaboration portals have become integral for real-time data exchange, fostering enhanced transparency and compliance across geographically dispersed teams.

These technological breakthroughs coincided with a shift toward more hybridized service offerings. Traditional full-service models are increasingly complemented by specialized functional service provider arrangements, enabling clients to maintain direct oversight of critical study components while outsourcing noncore functions. As a result, service providers are expanding niche capabilities-such as advanced biomarker discovery or adaptive trial management-to differentiate their value proposition and forge deeper partnerships.

Moreover, sustainability considerations and social responsibility initiatives are influencing provider selection. Clients now prioritize partners with robust environmental, social and governance frameworks, viewing these commitments as indicators of operational resilience and ethical stewardship. As the industry evolves, service organizations that integrate cutting-edge technologies with flexible operating models and strong ESG practices will be best positioned to lead the next wave of outsourcing innovation.

Unpacking the Broad Economic and Trade Policy Effects of the United States Tariffs on Biotechnology and Pharma Outsourcing in 2025

The imposition of new tariff regimes by the United States in 2025 has introduced a complex layer of cost and compliance considerations for sourcing laboratory supplies, active pharmaceutical ingredients and equipment from overseas partners. Manufacturers and clinical research organizations reliant on global supply chains have encountered elevated duties, prompting a reassessment of supplier portfolios and logistics networks. To manage these headwinds, many stakeholders are exploring near-shoring options and forging partnerships with domestic contract development and manufacturing organizations to circumvent tariff exposures.

At the same time, increased duties on specialized reagents and analytical instruments have led to pricing pressures across preclinical and clinical development activities. Service providers are responding by negotiating volume discounts, implementing consolidated shipping strategies and adopting lean inventory practices. These adjustments have delivered near-term cost relief but also introduced complexity into demand forecasting and capacity planning.

Strategically, the tariff landscape has incentivized dual-sourcing frameworks to mitigate single-source vulnerabilities. By diversifying procurement channels and investing in regional manufacturing footprints, companies can better manage financial risks and maintain continuity. In this evolving trade policy environment, proactive supply chain optimization and collaborative vendor ecosystems are emerging as critical enablers for sustaining efficient outsourcing operations.

Uncovering Segmentation Insights That Illuminate How Service Types Outsourcing Models Company Sizes Therapeutic Areas and Provider Types Shape Industry Growth

A rigorous examination of market segmentation uncovers nuanced demand drivers across a spectrum of service types ranging from clinical trial phases to complex regulatory strategy support. Clinical trial services spanning phases I through IV continue to capture significant attention as sponsors seek end-to-end patient recruitment and site management expertise, while consulting services encompassing M&A advisory and market access strategy are increasingly leveraged to navigate changing reimbursement landscapes.

Within manufacturing, specialized contract development and manufacturing organizations offering formulation development and scale-up capabilities are gaining traction, especially for novel modalities. Preclinical suppliers delivering bioanalytical testing and toxicology assessments play a critical role in de-risking early-stage assets, while pharmacovigilance and quality management services ensure rigorous safety monitoring throughout the product lifecycle. Moreover, research and development firms focusing on assay development, biomarker discovery and target validation provide indispensable insights that refine lead optimization and accelerate translational research.

The mode of outsourcing further differentiates strategic alignment: full-service partnerships deliver integrated program management, whereas functional service provider models and project-based engagements offer targeted flexibility. Additionally, the interplay between large enterprises and small to medium-sized biotechnology firms shapes procurement preferences, with larger sponsors often favoring comprehensive end-to-end solutions while emerging companies selectively outsource high-value research tasks. Finally, therapeutic area specialization and provider type-ranging from contract research to data management and regulatory affairs firms-reflect diverse competency needs and drive differential growth trajectories across the industry.

Analyzing the Unique Regional Drivers Regulatory Landscapes and Innovation Capacities Shaping the Americas EMEA and AsiaPacific Outsourcing Sectors

Regional dynamics reveal distinct innovation ecosystems and regulatory frameworks that influence outsourcing strategies. In the Americas, a robust concentration of biotech hubs and top-tier clinical sites drives demand for full-service solutions, while proactive trade policies and incentives support domestic manufacturing expansion. Shifting reimbursement models and an emphasis on patient-centric trials further spur growth in decentralized clinical service offerings.

Across Europe, the Middle East and Africa, harmonized regulatory initiatives such as the EU Clinical Trials Regulation are fostering greater cross-border collaboration and standardization in safety reporting. This regulatory convergence, combined with established contract research infrastructure, has elevated the region's appeal for midstage and late-stage clinical programs. At the same time, emerging markets within the Middle East and Africa are attracting investments in site development and pharmacovigilance capabilities, underpinned by government-sponsored research partnerships.

In the AsiaPacific corridor, rapid capacity expansion in contract development and manufacturing is reshaping global supply chain architectures. Nations across the region are investing heavily in biotech clusters, incentivizing API production and advanced fill-finish platforms. The integration of digital health initiatives and supportive regulatory frameworks accelerates clinical trial innovation, making AsiaPacific an increasingly strategic destination for cost-efficient, high-quality outsourced services.

Evaluating the Competitive Approaches Partnerships and Growth Paths of Major Contract Research Manufacturing and Consulting Organizations Shaping Biopharma

Leading contract research organizations are differentiating through strategic alliances, geographic footprint expansion and end-to-end platform integrations. Several top players have pursued joint ventures with specialized biotech firms to co-develop niche capabilities in cell therapy manufacturing and advanced analytics. These partnerships enhance service portfolios and accelerate access to cutting-edge technologies.

Similarly, leading CDMOs are investing in modular facility designs that support agile production scale-up, addressing the growing demand for personalized medicine manufacturing. To strengthen downstream capabilities, some providers have acquired packaging and labeling specialists, thereby streamlining tech transfer processes and minimizing regulatory hurdles. Contract manufacturing organizations also continue to refine their quality and compliance frameworks to meet the stringent standards required for biologics and high-potency compounds.

Consulting firms and regulatory affairs specialists are forging closer collaborations with industry associations and regulatory agencies to influence policy dialogues and expedite dossier approvals. Data management and IT service providers, in turn, are embedding robust cybersecurity and AI-driven analytics into trial management systems to optimize data integrity and accelerate decision cycles. Collectively, these competitive strategies underscore the imperative for integrated service offerings and continuous innovation to maintain leadership positions in the biopharma outsourcing arena.

Providing Actionable Strategic Recommendations for Biopharma Outsourcing Leaders to Optimize Service Delivery Innovation and Operational Resilience

Industry leaders should prioritize investments in digital platforms that facilitate seamless collaboration across global project teams and accelerate real-time data visibility. Implementing advanced analytics and AI-driven decision support tools will not only streamline trial design and patient recruitment but also enhance risk management in chain-of-custody and quality oversight.

Furthermore, building resilient supply chains through diversified sourcing and near-shoring strategies can mitigate tariff-induced cost fluctuations and regulatory uncertainties. Organizations should cultivate strategic alliances with regional manufacturers and logistics partners to bolster capacity flexibility and accelerate response times during demand surges.

In parallel, fostering deep specialized expertise within niche therapeutic and technical domains can drive competitive differentiation. By aligning service offerings with emerging modalities such as cell and gene therapy, companies can capture higher-value contracts and strengthen long-term client relationships. Lastly, embedding robust environmental, social and governance principles into operational frameworks will not only address stakeholder expectations but also signal a commitment to sustainable and ethical practices, reinforcing brand integrity and stakeholder trust.

Detailing the Rigorous Multimodal Research Methodology Combining Primary Expert Interviews Comprehensive Secondary Research and Data Triangulation Approaches

This research employs a comprehensive multimodal approach beginning with an extensive review of peer-reviewed publications, industry white papers and regulatory filings to construct a solid secondary data foundation. Key insights from government databases and specialized trade reports were synthesized to validate overarching market trends and policy developments.

Primary research involved in-depth interviews with senior executives at leading service providers, global biopharma sponsors and regulatory experts to capture firsthand perspectives on operational challenges and emerging opportunities. Respondent feedback was systematically triangulated with quantitative and qualitative data points to ensure robust findings.

Data analysis combined thematic content evaluation with cross-functional benchmarking, enabling identification of service innovation patterns and competitive differentiation strategies. Finally, the integrated methodology was governed by strict data validation protocols, ensuring the reliability and reproducibility of insights while maintaining transparency of assumptions and limitations throughout the research lifecycle.

Concluding with Holistic Reflections Synthesizing Key Trends Strategic Implications and Future Perspectives for Pharmaceutical Service Outsourcing Stakeholders

The outsourcing ecosystem for biotechnology and pharmaceutical services is rapidly maturing, fueled by technological breakthroughs, evolving trade policies and shifting client preferences. Strategic collaborations, digital transformation and regional expansion have emerged as pivotal levers for growth and resilience. As companies adapt to these imperatives, they must balance the need for specialized expertise with the efficiencies offered by integrated service models.

Moreover, trade-driven cost pressures underscore the importance of supply chain diversification and near-shore manufacturing investments. Regulatory harmonization efforts across major markets continue to streamline clinical development pathways, yet demand for localized compliance expertise remains high. Segmentation insights reveal that no single operating model will suffice; rather, success hinges on the ability to tailor services to sponsor priorities-whether managing complex trial phases, navigating market access challenges or scaling novel therapy production.

Ultimately, industry participants that align strategic investments in technology, partnerships and ESG stewardship will be best positioned to capture emerging opportunities and mitigate systemic risks. The path forward is defined by agility, specialization and sustained innovation across the global outsourcing value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rapid adoption of artificial intelligence platforms enabling accelerated drug discovery in contract research services
  • 5.2. Growing demand for personalized medicine leading to expansion of specialized outsourcing solutions
  • 5.3. Surge in cell and gene therapy outsourcing requiring specialized manufacturing capacity expansions
  • 5.4. Integration of sustainability and green chemistry practices in pharmaceutical outsourcing operations
  • 5.5. Expanding role of real world evidence and data analytics in shaping outsourcing clinical trial strategies
  • 5.6. Consolidation among CDMOs driving strategic partnerships and capacity optimization in biomanufacturing services
  • 5.7. Regulatory harmonization initiatives influencing global outsourcing of clinical trials and drug approvals
  • 5.8. Increased focus on risk mitigation and supply chain resilience in pharmaceutical service outsourcing agreements
  • 5.9. Emergence of digital patient engagement tools transforming site management and remote monitoring in clinical trials
  • 5.10. Adoption of continuous manufacturing processes accelerating biologics production in outsourced contract facilities

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Type

  • 8.1. Introduction
  • 8.2. Clinical Trial Services
    • 8.2.1. Phase I
    • 8.2.2. Phase II
    • 8.2.3. Phase III
    • 8.2.4. Phase IV
  • 8.3. Consulting Services
    • 8.3.1. M&A Advisory
    • 8.3.2. Market Access & Reimbursement Consulting
    • 8.3.3. Portfolio Management
    • 8.3.4. Strategic Consulting
  • 8.4. Manufacturing Services
    • 8.4.1. API Production
    • 8.4.2. Contract Development & Manufacturing Organization (CDMO) Services
    • 8.4.3. Fill-Finish Services
    • 8.4.4. Formulation Development
    • 8.4.5. Packaging & Labeling
    • 8.4.6. Scale-Up & Tech Transfer
  • 8.5. Pharmacovigilance Services
  • 8.6. Preclinical Services
    • 8.6.1. Animal Studies
    • 8.6.2. Bioanalytical Testing
    • 8.6.3. DMPK Studies
    • 8.6.4. Pharmacology Studies
    • 8.6.5. Toxicology Testing
  • 8.7. Quality Management Services
  • 8.8. Regulatory Affairs Services
    • 8.8.1. Agency Communication & Representation
    • 8.8.2. Dossier Preparation
    • 8.8.3. Labeling & Packaging Compliance
    • 8.8.4. Pharmacovigilance & Safety Monitoring
    • 8.8.5. Regulatory Strategy & Submissions
  • 8.9. Research & Development Services
    • 8.9.1. Assay Development
    • 8.9.2. Biomarker Discovery
    • 8.9.3. Lead Identification & Optimization
    • 8.9.4. Target Validation

9. Biotechnology & Pharmaceutical Services Outsourcing Market, by Mode of Outsourcing

  • 9.1. Introduction
  • 9.2. Full-Service Outsourcing
  • 9.3. Functional Service Provider (FSP) Model
  • 9.4. Tactical/Project-Based Outsourcing

10. Biotechnology & Pharmaceutical Services Outsourcing Market, by Company Size

  • 10.1. Introduction
  • 10.2. Large Enterprises
  • 10.3. Small & Medium Enterprises (SMEs)

11. Biotechnology & Pharmaceutical Services Outsourcing Market, by Therapeutic Area

  • 11.1. Introduction
  • 11.2. Cardiovascular
  • 11.3. Dermatology
  • 11.4. Gastroenterology
  • 11.5. Immunology
  • 11.6. Infectious Diseases
  • 11.7. Metabolic Disorders
  • 11.8. Neurology
  • 11.9. Oncology
  • 11.10. Pediatrics
  • 11.11. Rare Diseases
  • 11.12. Respiratory

12. Biotechnology & Pharmaceutical Services Outsourcing Market, by Service Provider Type

  • 12.1. Introduction
  • 12.2. Consulting Firms
  • 12.3. Contract Development & Manufacturing Organizations (CDMOs)
  • 12.4. Contract Manufacturing Organizations (CMOs)
  • 12.5. Contract Research Organizations (CROs)
  • 12.6. Data Management & IT Service Providers
  • 12.7. Regulatory Affairs Firms

13. Americas Biotechnology & Pharmaceutical Services Outsourcing Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Biotechnology & Pharmaceutical Services Outsourcing Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Biotechnology & Pharmaceutical Services Outsourcing Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AmerisourceBergen Corporation
    • 16.3.2. Catalent, Inc.
    • 16.3.3. CEVA Logistics AG
    • 16.3.4. Charles River Laboratories, Inc.
    • 16.3.5. Concept Heidelberg GmbH
    • 16.3.6. Curia Global, Inc.
    • 16.3.7. Dalton Pharma Services by Seikagaku Corporation
    • 16.3.8. DHL International GmbH
    • 16.3.9. Eurofins Scientific (Ireland) Limited
    • 16.3.10. Evotec SE
    • 16.3.11. GenScript Biotech Corporation
    • 16.3.12. Icon PLC
    • 16.3.13. IQVIA HOLDINGS, INC.
    • 16.3.14. Laboratory Corporation of America Holdings
    • 16.3.15. Lachman Consultant Services, Inc.
    • 16.3.16. McKesson Corporation by Aurelius Group
    • 16.3.17. Medpace Holdings, Inc.
    • 16.3.18. Parexel International Corporation
    • 16.3.19. Syneos Health, Inc.
    • 16.3.20. Thermo Fisher Scientific Inc.
    • 16.3.21. WuXi AppTec Co., Ltd.

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHAI
  • FIGURE 26. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHSTATISTICS
  • FIGURE 27. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHCONTACTS
  • FIGURE 28. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE I, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE II, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE III, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHASE IV, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY M&A ADVISORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MARKET ACCESS & REIMBURSEMENT CONSULTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PORTFOLIO MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STRATEGIC CONSULTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY API PRODUCTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION (CDMO) SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FILL-FINISH SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FORMULATION DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PACKAGING & LABELING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SCALE-UP & TECH TRANSFER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ANIMAL STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOANALYTICAL TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DMPK STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOLOGY STUDIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY QUALITY MANAGEMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY AGENCY COMMUNICATION & REPRESENTATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DOSSIER PREPARATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LABELING & PACKAGING COMPLIANCE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PHARMACOVIGILANCE & SAFETY MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY STRATEGY & SUBMISSIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ASSAY DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TARGET VALIDATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FULL-SERVICE OUTSOURCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY FUNCTIONAL SERVICE PROVIDER (FSP) MODEL, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 101. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY TACTICAL/PROJECT-BASED OUTSOURCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 103. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 105. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 107. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES (SMES), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 109. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 111. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 113. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DERMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 115. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 117. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 119. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 121. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 123. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 125. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 127. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 129. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RARE DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 131. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESPIRATORY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 133. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 137. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 139. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS (CMOS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 141. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 143. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY DATA MANAGEMENT & IT SERVICE PROVIDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 145. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS FIRMS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 147. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 151. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 153. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 155. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 157. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 159. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 161. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 163. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 165. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 167. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 179. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 180. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 181. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 182. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED STATES BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 195. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 198. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 199. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 200. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 201. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 202. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 203. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 204. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 205. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 206. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 207. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 208. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 209. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 210. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 211. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 212. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 213. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 214. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 215. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. CANADA BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 220. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CLINICAL TRIAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 221. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 222. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY CONSULTING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 223. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2018-2024 (USD MILLION)
  • TABLE 224. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MANUFACTURING SERVICES, 2025-2030 (USD MILLION)
  • TABLE 225. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2018-2024 (USD MILLION)
  • TABLE 226. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY PRECLINICAL SERVICES, 2025-2030 (USD MILLION)
  • TABLE 227. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2018-2024 (USD MILLION)
  • TABLE 228. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY REGULATORY AFFAIRS SERVICES, 2025-2030 (USD MILLION)
  • TABLE 229. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2018-2024 (USD MILLION)
  • TABLE 230. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY RESEARCH & DEVELOPMENT SERVICES, 2025-2030 (USD MILLION)
  • TABLE 231. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2018-2024 (USD MILLION)
  • TABLE 232. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY MODE OF OUTSOURCING, 2025-2030 (USD MILLION)
  • TABLE 233. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2018-2024 (USD MILLION)
  • TABLE 234. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY COMPANY SIZE, 2025-2030 (USD MILLION)
  • TABLE 235. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 236. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
  • TABLE 237. MEXICO BIOTECHNOLOGY & PHARMACEUTICAL SERVICES OUTSOURCING MARKET SIZE, BY SERVICE PROVIDER TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. MEXICO BIOTECHNOLOGY & P